Cyganek A, Pietrzak B, Kociszewska-Najman B, Sanko-Resmer J, Paczek L, Wielgos M
The 1st Department of Obstetrics and Gynaecology, The Medical University of Warsaw, Warsaw, Poland.
Transplant Proc. 2011 Oct;43(8):2970-2. doi: 10.1016/j.transproceed.2011.08.054.
Pregnancies in renal transplant patients are considered to be high risk. Anemia is one of the major complications of pregnancy occurring among 65% to 85% of cases in this setting, especially since these patients carry additional risk factors. Herein we have presented five renal transplant recipients who were women who were treated with human recombinant erythropoietin due to severe anemia that developed during pregnancy. Hemoglobin levels below 9 g/dL after 3 weeks of oral iron administration were assumed to be qualifying criteria for erythropoietin treatment. No complication was observed to be associated with the treatment. Two of the five patients required blood transfusions despite erythropoietin administration. Two cases delivered small for gestational fetus age. Erythropoietin therapy in pregnant kidney transplant recipients should be considered to be a safe method to reduce the need for blood transfusions.
肾移植患者的妊娠被认为具有高风险。贫血是妊娠的主要并发症之一，在这种情况下，65%至85%的病例会出现贫血，特别是因为这些患者还存在其他风险因素。在此，我们介绍了五名肾移植受者，她们均为女性，因妊娠期间出现严重贫血而接受了重组人促红细胞生成素治疗。口服铁剂3周后血红蛋白水平低于9 g/dL被视为促红细胞生成素治疗的合格标准。未观察到与治疗相关的并发症。五名患者中有两名尽管接受了促红细胞生成素治疗仍需要输血。两名患者分娩出小于孕周的胎儿。对于妊娠肾移植受者，促红细胞生成素治疗应被视为一种减少输血需求的安全方法。
